Mozer J L, Gibey R, Dupond J L, Henry J C
Laboratoire de Biochimie, Centre Hospitalier et Universitaire, Besançon, France.
Pathol Biol (Paris). 1988 Mar;36(3):230-4.
Lysosomal enzyme activities can be modified by aminoglycosides. In this study, we have investigated the "in vitro" effect of gentamicin (G), tobramycin (T), dibekacin (D), netilmicin (N) and amikacin (AK) on urinary N-acétyl-beta-D-glucosaminidase (NAG) and its isoenzymatic forms. G, D and N are activators of this enzyme, specifically of the B isoenzymatic form, while T inhibits slightly the A, I1 and I2 forms. At usual therapeutical urinary concentration of AK during antibiotherapy, NAG and its isoenzymes are very strongly inhibited (more than 65%). Dixon plot indicates that the nature of inhibition is "competitive apparent", without binding of inhibitor to the active site of the enzyme. This binding of aminoglycosides to NAG as to other lysosomal enzymes may represent one of the accumulation mechanisms of aminoglycosides in tubular cells. It can explain the specific alteration of lysosomes during nephrotoxic antibiotherapy. Consequently, when urinary NAG determination is used as indicator of nephrotoxicity during therapy, the activation or inhibition of the enzyme by aminoglycosides could lead to false assay results.
溶酶体酶活性可被氨基糖苷类药物改变。在本研究中,我们调查了庆大霉素(G)、妥布霉素(T)、地贝卡星(D)、奈替米星(N)和阿米卡星(AK)对尿N - 乙酰 - β - D - 氨基葡萄糖苷酶(NAG)及其同工酶形式的“体外”作用。G、D和N是该酶的激活剂,特别是对B同工酶形式,而T对A、I1和I2形式有轻微抑制作用。在抗菌治疗期间AK通常的治疗性尿浓度下,NAG及其同工酶受到非常强烈的抑制(超过65%)。迪克森图表明抑制的性质是“竞争性表观”,抑制剂不与酶的活性位点结合。氨基糖苷类与NAG以及其他溶酶体酶的这种结合可能代表了氨基糖苷类在肾小管细胞中的蓄积机制之一。这可以解释肾毒性抗菌治疗期间溶酶体的特异性改变。因此,当在治疗期间将尿NAG测定用作肾毒性指标时,氨基糖苷类对该酶的激活或抑制可能导致错误的检测结果。